|
Dr. Michael Flavin is a Managing Director of Flavin Ventures, LLC the group that founded and launched Shamrock Structures. He is presently the Chief Executive Officer of Advanced Life Sciences, Inc. He was the founder, CEO, and Chairman of MediChem Life Sciences, Inc. (NASDAQ:MCLS). Dr. Flavin took MediChem from start-up in 1987 through many stages of development including the successful completion of MediChem's $35M private placement in 1999, the acquisition and integration of ThermoGen and Emerald Biostructures and MediChem's October, 2000 $54M IPO. He oversaw formation of the AXAS subsidiary and contract with the U.S. Department of Energy and management of the COMCAT beam line at the Advanced Photon Source at Argonne National Laboratory. MediChem was acquired in 2002 by deCODE genetics (NASDAQ:DCGN) for $83M in stock. Dr. Flavin received a Bachelor of Science in Chemistry from the University of Notre Dame, a Ph.D. in Medicinal Chemistry from the University of Illinois at Chicago, and completed a postdoctoral fellowship at Harvard University. Prior to founding MediChem, Dr. Flavin worked as a Senior Research Associate for Baxter International. | 